iZafe Group (IZAFE-B.ST) Stock Analysis & AI Equity Report

Medical - Instruments & Supplies SEK Explore free reports

iZafe Group (IZAFE-B.ST) overview

iZafe Group (IZAFE-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, iZafe Group reported revenue of SEK 6.0m and operating profit of SEK -18.4m; the year-end share price was 0.48 SEK and market capitalisation was SEK 162m. iZafe Group is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get iZafe Group's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 11.7mFY 2025
Share price0.48 SEKFY 2025 year end
RevenueSEK 6.0mFY 2025
Operating profitSEK -18.4mFY 2025
Net earningsSEK -16.7mFY 2025
Market capitalisationSEK 162mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About iZafe Group

iZafe Group AB develops and markets digital medical solutions for safer medication management at home. Its main products are the Dosell medication dispenser and the Pilloxa smart pillbox platform, which support dose administration, reminders, and patient data capture. The company sells through partners to households, healthcare providers, and pharmaceutical customers in Sweden and other markets.

Generate the iZafe Group report

iZafe Group is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for iZafe Group and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on iZafe Group

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.